Schug et al's article on psychophysiological and behavioural characteristics of individuals with comorbid antisocial personality disorder (ASPD) and schizophrenia-spectrum personality disorder (SSPD) opens the possibility of the existence of a new spectrum of personality disorders. But reading the article with care raises some questions.
Authors' reply:
We are grateful for thoughtful critical points raised by Drs Sekar and Ganapathy. We agree that the prevalence of personality disorders in our sample is high. This sample was chosen for its elevated rates of ASPD -perhaps attributable to a downward drift in occupational functioning due to antisocial features. It is certainly vulnerable to selection bias for several reasons (among them being the fact that some individuals did not meet inclusion criteria), and the 52.4% personality disorder prevalence rate should not be mistaken for a typical community population base rate, or a general rate applying to other populations (claims which were not made in our paper). Also, the prevalence rates of other individual personality disorders (e.g. narcissistic personality disorder -around 3%) were consistent with general population estimates.
1,2 Additionally, our focus was the characteristics of this ASPD/SSPD group, rather than making any assertions about its prevalence in the general population.
On reading the correspondents' comment about SSPD comorbidity with other personality disorders, we too became intrigued with this possibility and have since conducted further analyses. These revealed, among the other personality disorders, significant SSPD comorbidity only with narcissistic personality disorder. In fact, all three of our sample's individuals with narcissistic personality disorder had comorbid ASPD and SSPD. This additional comorbidity among our ASPD/SSPD group is not surprising, given the problematically high overlap of narcissistic personality disorder with ASPD and other Cluster B disorders, 2, 3 the conceptual link between the narcissistic and antisocial personalities (e.g. Kernberg's 'malignant narcissism'), 3 and the positive correlations observed between narcissistic personality disorder and other antisocial personalities such as psychopathy. 4 We still believe ASPD/SSPD comorbidity to be meaningful, and not an artifact of the sample, as 50% of individuals with comorbid ASPD/SSPD were not characterised by any additional Axis II comorbidity.
We agree that the frontal cortex (specifically the prefrontal cortex) may be a common abnormality and that this needs further investigation. Clearly, additional research is needed on this comorbid group, in both clinical and nonclinical populationsincluding 'unique' community samples such as our own.
Patient choice in psychiatry in low-and middleincome countries
Samele et al 1 have highlighted the implications of patient choice in psychiatry and some of its main challenges. The importance of a patient-oriented approach in psychiatry has even been emphasised in the World Health Report.
2 Patients seem to want more say in their treatment decisions, to receive appropriate information on their condition and make decisions concerning the management of their illness.
3 Psychiatry is a particularly challenging area with regard to this, because mental illness can affect both understanding and decision-making abilities. This topic has significance particularly to low-and middle-income countries such as Sri Lanka. The attitudes of patients and choice of therapy in low-and middle-income countries may differ from those in high-income countries as cultural norms and beliefs play a major role in decision-making. 4 Also, almost all the time, patients depend on the therapist to make decisions regarding their treatment either because they themselves are not knowledgeable enough or they think the therapist knows best. At present, suing by patients is found less frequently in low-and middle-income countries compared with the West, hence therapists are not under pressure when making decisions. This may contribute to the maintenance of the 'therapist-centred' approach in the management of patients in our part of the world. Another reason which makes patient choice less feasible in low-and middle-income countries is the limited number of therapeutic options, owing to lack of resources. This sometimes leads to medications being the only available option although other treatment modalities are indicated for the particular condition. Another factor which might impede patient choice is the lack of a proper mental health act. Some low-and middle-income countries either do not have a mental health act 2 or the existing mental health acts are archaic, were developed during the pre-antipsychotic era and are not at all patient centred. Psychiatrists and policy makers, particularly in low-and middle-income countries, should be aware of these important issues when health plans are made and implemented.
